nach oben

Erschienen in:

01.10.2019 | New Imaging Techniques (S Rais-Bahrami and K Porter, Section Editors)

Developing a National Center of Excellence for Prostate Imaging

verfasst von: Annerleim Walton-Diaz, Manuel Madariaga-Venegas, Nicolas Aviles, Juan Carlos Roman, Ivan Gallegos, Mauricio Burotto

Erschienen in: Current Urology Reports | Ausgabe 10/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The purpose of this review is to summarize the most current literature regarding the most important aspects to consider when developing a center of excellence for prostate imaging and biopsy.

Recent Findings

Multiparametric MRI (mp-MRI) has changed the way we diagnose and treat prostate cancer. This imaging modality allows for more precise identification of areas suspicious in terms of harboring prostate cancer, enabling performance of targeted mp-MRI-guided biopsies that have been demonstrated to yield superior cancer detection rates. Centers worldwide are increasingly adopting this technology. However, obtaining results comparable with those findings published in the literature can be challenging. The imaging and biopsy process entails the need for a multidisciplinary team including a dedicated radiologist, urologist, and pathologist. Adequate mp-MRI interpretation for accurate lesion identification, acquaintance with the biopsy technique selected, and precise characterization of Gleason Score/Grade Groupings are equal determinants of accurate biopsy results. Furthermore, all specialists are required to attain appropriate learning curves to ensure optimal results.

Summary

In this review, we characterize crucial aspects to consider when developing a center of excellence for prostate imaging and biopsy as well as insights regarding how to implement them.

Zaytoun OM, Moussa AS, Gao T, Fareed K, Jones JS. Office based transrectal saturation biopsy improves prostate cancer detection compared to extended biopsy in the repeat biopsy population. J Urol. 2011;186(3):850–4.CrossRefPubMed

Norberg M, Egevad L, Holmberg L, Sparén P, Norlén BJ, Busch C. The sextant protocol for ultrasound-guided core biopsies of the prostate underestimates the presence of cancer. Urology. 1997;50(4):562–6.CrossRefPubMed

Noguchi M, et al. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer. J Urol. 2001;166(1):104–9 discussion 109–10.CrossRefPubMed

Verma S, Choyke PL, Eberhardt SC, Oto A, Tempany CM, Turkbey B, et al. The current state of MR imaging-targeted biopsy techniques for detection of prostate cancer. Radiology. 2017;285(2):343–56.CrossRefPubMedPubMedCentral

Siddiqui MM, Rais-Bahrami S, Turkbey B, George AK, Rothwax J, Shakir N, et al. Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. JAMA. 2015;313(4):390–7.CrossRefPubMedPubMedCentral

Murphy G, Haider M, Ghai S, Sreeharsha B. The expanding role of MRI in prostate cancer. AJR Am J Roentgenol. 2013;201(6):1229–38.CrossRefPubMed

Raskolnikov D, George AK, Rais-Bahrami S, Turkbey B, Shakir NA, Okoro C, et al. Multiparametric magnetic resonance imaging and image-guided biopsy to detect seminal vesicle invasion by prostate cancer. J Endourol. 2014;28(11):1283–9.CrossRefPubMedPubMedCentral

Raskolnikov D, George AK, Rais-Bahrami S, Turkbey B, Siddiqui MM, Shakir NA, et al. The role of magnetic resonance image guided prostate biopsy in stratifying men for risk of extracapsular extension at radical prostatectomy. J Urol. 2015;194(1):105–11.CrossRefPubMed

Mehralivand S, Shih JH, Harmon S, Smith C, Bloom J, Czarniecki M, et al. A grading system for the assessment of risk of extraprostatic extension of prostate cancer at multiparametric MRI. Radiology. 2019;290(3):709–19.CrossRefPubMed

10.

Stamatakis L, Siddiqui MM, Nix JW, Logan J, Rais-Bahrami S, Walton-Diaz A, et al. Accuracy of multiparametric magnetic resonance imaging in confirming eligibility for active surveillance for men with prostate cancer. Cancer. 2013;119(18):3359–66.CrossRefPubMedPubMedCentral

11.

Walton Diaz A, et al. Use of serial multiparametric magnetic resonance imaging in the management of patients with prostate cancer on active surveillance. Urol Oncol. 2015;33(5):202 e1–7.CrossRef

12.

• Yarlagadda VK, et al. MRI/US fusion-guided prostate biopsy allows for equivalent cancer detection with significantly fewer needle cores in biopsy-naive men. Diagn Interv Radiol. 2018;24(3):115–20. This article addresses the superior efficiency in detection of prostate cancer for fusion biopsy over systematic 12-core TRUS biopsy. CrossRefPubMedPubMedCentral

13.

Vourganti S, Rastinehad A, Yerram NK, Nix J, Volkin D, Hoang A, et al. Multiparametric magnetic resonance imaging and ultrasound fusion biopsy detect prostate cancer in patients with prior negative transrectal ultrasound biopsies. J Urol. 2012;188(6):2152–7.CrossRefPubMedPubMedCentral

14.

•• Truong M, et al. Multi-institutional nomogram predicting benign prostate pathology on magnetic resonance/ultrasound fusion biopsy in men with a prior negative 12-core systematic biopsy. Cancer. 2018;124(2):278–85. This article presents a novel tool to aid clinicians in the process of determining which patients may benefit the most of a fusion biopsy when presented with patients with prior negative biopsy. CrossRefPubMed

15.

Volkin D, Turkbey B, Hoang AN, Rais-Bahrami S, Yerram N, Walton-Diaz A, et al. Multiparametric magnetic resonance imaging (MRI) and subsequent MRI/ultrasonography fusion-guided biopsy increase the detection of anteriorly located prostate cancers. BJU Int. 2014;114(6b):E43–9.CrossRefPubMedPubMedCentral

16.

Ahmed HU, Brown LC, Kaplan R, Parker C, Emberton M. Diagnostic accuracy of the PROMIS study - authors’ reply. Lancet. 2017;390(10092):362.CrossRefPubMed

17.

Kasel-Seibert M, Lehmann T, Aschenbach R, Guettler FV, Abubrig M, Grimm MO, et al. Assessment of PI-RADS v2 for the detection of prostate cancer. Eur J Radiol. 2016;85(4):726–31.CrossRef

18.

•• Kasivisvanathan V, et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med. 2018;378(19):1767–77. This article presents level 1 evidence supporting the use of prostate MRI and targeted biopsy in the initial diagnosis of prostate cancer. CrossRefPubMed

19.

Turkbey B, Rosenkrantz AB, Haider MA, Padhani AR, Villeirs G, Macura KJ, et al. Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2. Eur Urol. 2019;76:340–51.CrossRefPubMed

20.

Mirak SA, Shakeri S, Bajgiran AM, Felker ER, Sung KH, Asvadi NH, et al. Three tesla multiparametric magnetic resonance imaging: comparison of performance with and without endorectal coil for prostate cancer detection, PI-RADS version 2 category and staging with whole mount histopathology correlation. J Urol. 2019;201(3):496–502.CrossRefPubMed

21.

Ullrich T, Quentin M, Oelers C, Dietzel F, Sawicki LM, Arsov C, et al. Magnetic resonance imaging of the prostate at 1.5 versus 3.0T: a prospective comparison study of image quality. Eur J Radiol. 2017;90:192–7.CrossRefPubMed

22.

Fulgham PF, Rukstalis DB, Turkbey IB, Rubenstein JN, Taneja S, Carroll PR, et al. AUA policy statement on the use of multiparametric magnetic resonance imaging in the diagnosis, staging and management of prostate cancer. J Urol. 2017;198(4):832–8.CrossRefPubMed

23.

Sarkar S, Verma S. MR imaging-targeted prostate biopsies. Radiol Clin N Am. 2018;56(2):289–300.CrossRefPubMed

24.

Zhang L, Tang M, Chen S, Lei X, Zhang X, Huan Y. A meta-analysis of use of prostate imaging reporting and data system version 2 (PI-RADS V2) with multiparametric MR imaging for the detection of prostate cancer. Eur Radiol. 2017;27(12):5204–14.CrossRefPubMed

25.

Greer MD, Brown AM, Shih JH, Summers RM, Marko J, Law YM, et al. Accuracy and agreement of PIRADSv2 for prostate cancer mpMRI: a multireader study. J Magn Reson Imaging. 2017;45(2):579–85.CrossRefPubMed

26.

Smith CP, et al. Intra- and interreader reproducibility of PI-RADSv2: a multireader study. J Magn Reson Imaging. 2018.

27.

Stolk TT, de Jong IJ, Kwee TC, Luiting HB, Mahesh SVK, Doornweerd BHJ, et al. False positives in PIRADS (V2) 3, 4, and 5 lesions: relationship with reader experience and zonal location. Abdom Radiol (NY). 2019;44(3):1044–51.CrossRef

28.

Mullerad M, Hricak H, Wang L, Chen HN, Kattan MW, Scardino PT. Prostate cancer: detection of extracapsular extension by genitourinary and general body radiologists at MR imaging. Radiology. 2004;232(1):140–6.CrossRefPubMed

29.

Rosenkrantz AB, Ayoola A, Hoffman D, Khasgiwala A, Prabhu V, Smereka P, et al. The learning curve in prostate MRI interpretation: self-directed learning versus continual reader feedback. AJR Am J Roentgenol. 2017;208(3):W92–W100.CrossRefPubMed

30.

Kasabwalaa K, Patel N, Cricco-Lizzaa E, Shimpib AA, Wenga S, Buchmannb RM, et al. The learning curve for magnetic resonance imaging/ultrasound fusion-guided prostate biopsy. Eur Urol. 2018;In Press(In Press):In Press.

31.

Meng X, Rosenkrantz AB, Huang R, Deng FM, Wysock JS, Bjurlin MA, et al. The institutional learning curve of magnetic resonance imaging-ultrasound fusion targeted prostate biopsy: temporal improvements in cancer detection in 4 years. J Urol. 2018;200(5):1022–9.CrossRefPubMed

32.

Rouviere O, et al. Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study. Lancet Oncol. 2019;20(1):100–9.CrossRefPubMed

33.

Xu S, Kruecker J, Turkbey B, Glossop N, Singh AK, Choyke P, et al. Real-time MRI-TRUS fusion for guidance of targeted prostate biopsies. Comput Aided Surg. 2008;13(5):255–64.CrossRefPubMedPubMedCentral

34.

Ukimura O, Desai MM, Palmer S, Valencerina S, Gross M, Abreu AL, et al. 3-Dimensional elastic registration system of prostate biopsy location by real-time 3-dimensional transrectal ultrasound guidance with magnetic resonance/transrectal ultrasound image fusion. J Urol. 2012;187(3):1080–6.CrossRefPubMed

35.

Natarajan S, Marks LS, Margolis DJA, Huang J, Macairan ML, Lieu P, et al. Clinical application of a 3D ultrasound-guided prostate biopsy system. Urol Oncol. 2011;29(3):334–42.CrossRefPubMedPubMedCentral

36.

Calio BP, Sidana A, Sugano D, Gaur S, Maruf M, Jain AL, et al. Risk of upgrading from prostate biopsy to radical prostatectomy pathology-does saturation biopsy of index lesion during multiparametric magnetic resonance imaging-transrectal ultrasound fusion biopsy help? J Urol. 2018;199(4):976–82.CrossRefPubMed

37.

Gordetsky JB, Thomas JV, Nix JW, Rais-Bahrami S. Higher prostate Cancer grade groups are detected in patients undergoing multiparametric MRI-targeted biopsy compared with standard biopsy. Am J Surg Pathol. 2017;41(1):101–5.CrossRefPubMed

38.

Djavan B, Kadesky K, Klopukh B, Marberger M, Roehrborn CG. Gleason scores from prostate biopsies obtained with 18-gauge biopsy needles poorly predict Gleason scores of radical prostatectomy specimens. Eur Urol. 1998;33(3):261–70.CrossRefPubMed

39.

Kuroiwa K, Shiraishi T, Naito S. Gleason score correlation between biopsy and prostatectomy specimens and prediction of high-grade Gleason patterns: significance of central pathologic review. Urology. 2011;77(2):407–11.CrossRefPubMed

40.

Cohen MS, Hanley RS, Kurteva T, Ruthazer R, Silverman ML, Sorcini A, et al. Comparing the Gleason prostate biopsy and Gleason prostatectomy grading system: the Lahey Clinic Medical Center experience and an international meta-analysis. Eur Urol. 2008;54(2):371–81.CrossRefPubMed

41.

Majoros A, Szász AM, Nyirády P, Székely E, Riesz P, Szendrői A, et al. The influence of expertise of the surgical pathologist to undergrading, upgrading, and understaging of prostate cancer in patients undergoing subsequent radical prostatectomy. Int Urol Nephrol. 2014;46(2):371–7.CrossRefPubMed

42.

Mortezavi A, Keller EX, Poyet C, Hermanns T, Saba K, Randazzo M, et al. Clinical impact of prostate biopsy undergrading in an academic and community setting. World J Urol. 2016;34(10):1481–90.CrossRefPubMed

43.

Allsbrook WC Jr, Mangold KA, Johnson MH, Lane RB, Lane CG, Epstein JI. Interobserver reproducibility of Gleason grading of prostatic carcinoma: general pathologist. Hum Pathol. 2001;32(1):81–8.CrossRefPubMed

44.

Gordetsky JB, Schultz L, Porter KK, Nix JW, Thomas JV, del Carmen Rodriguez Pena M, et al. Defining the optimal method for reporting prostate cancer grade and tumor extent on magnetic resonance/ultrasound fusion-targeted biopsies. Hum Pathol. 2018;76:68–75.CrossRefPubMed

45.

Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO classification of tumours of the urinary system and male genital organs-part a: renal, penile, and testicular tumours. Eur Urol. 2016;70(1):93–105.CrossRef

46.

Epstein JI, et al. The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol. 2016;40(2):244–52.

47.

Arsov C, Becker N, Rabenalt R, Hiester A, Quentin M, Dietzel F, et al. The use of targeted MR-guided prostate biopsy reduces the risk of Gleason upgrading on radical prostatectomy. J Cancer Res Clin Oncol. 2015;141(11):2061–8.CrossRefPubMed

48.

Kongnyuy M, George AK, Rastinehad AR, Pinto PA. Magnetic resonance imaging-ultrasound fusion-guided prostate biopsy: review of technology, techniques, and outcomes. Curr Urol Rep. 2016;17(4):32.CrossRefPubMedPubMedCentral

49.

Logan JK, Rais-Bahrami S, Turkbey B, Gomella A, Amalou H, Choyke PL, et al. Current status of magnetic resonance imaging (MRI) and ultrasonography fusion software platforms for guidance of prostate biopsies. BJU Int. 2014;114(5):641–52.CrossRefPubMedPubMedCentral

50.

Hadaschik BA, Kuru TH, Tulea C, Rieker P, Popeneciu IV, Simpfendörfer T, et al. A novel stereotactic prostate biopsy system integrating pre-interventional magnetic resonance imaging and live ultrasound fusion. J Urol. 2011;186(6):2214–20.CrossRefPubMed

51.

Halstuch D, Baniel J, Lifshitz D, Sela S, Ber Y, Margel D. Assessment of needle tip deflection during transrectal guided prostate biopsy: implications for targeted biopsies. J Endourol. 2018;32(3):252–6.CrossRefPubMed

52.

Westhoff N, Siegel FP, Hausmann D, Polednik M, von Hardenberg J, Michel MS, et al. Precision of MRI/ultrasound-fusion biopsy in prostate cancer diagnosis: an ex vivo comparison of alternative biopsy techniques on prostate phantoms. World J Urol. 2017;35(7):1015–22.CrossRefPubMed

Titel: Developing a National Center of Excellence for Prostate Imaging
verfasst von: Annerleim Walton-Diaz
Manuel Madariaga-Venegas
Nicolas Aviles
Juan Carlos Roman
Ivan Gallegos
Mauricio Burotto
Publikationsdatum: 01.10.2019
Verlag: Springer US
Erschienen in: Current Urology Reports / Ausgabe 10/2019
Print ISSN: 1527-2737
Elektronische ISSN: 1534-6285
DOI: https://doi.org/10.1007/s11934-019-0923-3

Neu im Fachgebiet Urologie

Patrone im Penis bringt Urologen in Gefahr

30.05.2024 Operationen am Penis Nachrichten

In Lebensgefahr brachte ein junger Mann nicht nur sich selbst, sondern auch das urologische Team, das ihm zu Hilfe kam: Er hatte sich zur Selbstbefriedigung eine scharfe Patrone in die Harnröhre gesteckt.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Fehlerkultur in der Medizin – Offenheit zählt!

28.05.2024 Fehlerkultur Podcast

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Developing a National Center of Excellence for Prostate Imaging